Telesis Bio gains on 2022 sales forecast raise
** Telesis Bio Inc's shares DNAY.O rise 6.6% to $1.80
premarket
** Healthcare service provider raises 2022 sales forecast to
between $23 million and $25 million from $22 million to $24
million previously urn:newsml:reuters.com:*:nGNX3v8N96
** Co's revenue in Q3 more than doubled to $6.7 million
compared with $2.8 million for the same period in 2021
** Up to Tuesday's close, stock down ~85% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))
Recent news on Telesis Bio
See all newsBrief: Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Brief: Telesis Bio Plans To Delist Its Securities From The Nasdaq Stock Market
Brief: Telesis Bio Says Co Entered Share Purchase Agreement With Yuan Yang To Sell All Of Outstanding Capital Stock Of Eton Bio
Telesis Bio Inc reports results for the quarter ended in June - Earnings Summary
Telesis Bio Inc expected to post a loss of $4.03 a share - Earnings Preview